Kathy Hopinkah Hannan
CIK 1767813 · View on SEC EDGAR ↗
Insider
First SEC filing: Jan. 10, 2020 · Latest: June 12, 2026
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 24 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | NLY | A | 8,641 | — | — | 44,348 Direct | +24.20% | Acquired | (price as of 2026-08-21) |
| June 11, 2025 | DNA | M | 10,822 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| June 11, 2025 | DNA | M | 10,822 | — | — | 15,003 Direct | +258.84% | Acquired | (price as of 2026-08-21) |
| May 15, 2025 | OTIS | A | 1,993 | $97.86 | $195,035 | 15,894 Direct | +14.34% | Acquired | -26.5% (price as of 2026-08-21) |
| June 13, 2024 | DNA | A | 571,428 | — | — | 571,428 Direct | — | Acquired | (price as of 2026-08-21) |
| June 13, 2024 | DNA | A | 432,900 | — | — | 432,900 Direct | — | Acquired | (price as of 2026-08-21) |
| June 12, 2024 | DNA | M | 105,263 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| June 12, 2024 | DNA | M | 105,263 | — | — | 167,249 Direct | +169.82% | Acquired | (price as of 2026-08-21) |
| May 16, 2024 | OTIS | A | 2,019 | $96.56 | $194,955 | 13,683 Direct | +17.31% | Acquired | -25.5% (price as of 2026-08-21) |
| Oct. 10, 2023 | CRS | A | 1,028 | — | — | 1,028 Direct | — | Acquired | (price as of 2026-08-21) |
| Oct. 10, 2023 | CRS | A | 1,912 | — | — | 6,953 Direct | +37.93% | Acquired | (price as of 2026-08-21) |
| June 16, 2023 | DNA | A | 139,860 | — | — | 139,860 Direct | — | Acquired | (price as of 2026-08-21) |
| June 16, 2023 | DNA | A | 105,263 | — | — | 105,263 Direct | — | Acquired | (price as of 2026-08-21) |
| May 18, 2023 | OTIS | A | 2,308 | $84.50 | $195,026 | 11,485 Direct | +25.15% | Acquired | -14.9% (price as of 2026-08-21) |
| Oct. 11, 2022 | CRS | A | 2,408 | — | — | 2,408 Direct | — | Acquired | (price as of 2026-08-21) |
| Oct. 11, 2022 | CRS | A | 3,646 | — | — | 4,978 Direct | +273.72% | Acquired | (price as of 2026-08-21) |
| Aug. 2, 2022 | DNA | A | 186,915 | — | — | 186,915 Direct | — | Acquired | (price as of 2026-08-21) |
| Aug. 2, 2022 | DNA | A | 84,216 | — | — | 84,216 Direct | — | Acquired | (price as of 2026-08-21) |
| Aug. 2, 2022 | DNA | A | 56,986 | — | — | 61,986 Direct | +1139.72% | Acquired | (price as of 2026-08-21) |
| May 19, 2022 | OTIS | A | 2,686 | $72.59 | $194,977 | 9,041 Direct | +42.27% | Acquired | -0.9% (price as of 2026-08-21) |
| April 13, 2022 | CRS | A | 4,991 | — | — | 4,991 Direct | — | Acquired | (price as of 2026-08-21) |
| April 13, 2022 | CRS | A | 1,324 | — | — | 1,324 Direct | — | Acquired | (price as of 2026-08-21) |
| April 27, 2021 | OTIS | A | 2,468 | $79.00 | $194,972 | 6,281 Direct | +64.73% | Acquired | -9.0% (price as of 2026-08-21) |
| May 11, 2020 | OTIS | A | 3,764 | $51.81 | $195,013 | 3,764 Direct | — | Acquired | 38.8% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | NLY | Deferred Stock Units | Common Stock (8,641) | — | — | 8,641 | Acquired |
| June 11, 2025 | DNA | Restricted Stock Units | Class A Common Stock (10,822) | — | — | 10,822 | Disposed |
| May 15, 2025 | OTIS | Deferred Stock Units | Common Stock (1,993) | — | — | 1,993 | Acquired |
| June 13, 2024 | DNA | Stock Option | Class A Common Stock | $0.46 | June 13, 2034 | 571,428 | Acquired |
| June 13, 2024 | DNA | Restricted Stock Units | Class A Common Stock (432,900) | — | — | 432,900 | Acquired |
| June 12, 2024 | DNA | Restricted Stock Units | Class A Common Stock (105,263) | — | — | 105,263 | Disposed |
| May 16, 2024 | OTIS | Deferred Stock Units | Common Stock (2,019) | — | — | 2,019 | Acquired |
| Oct. 10, 2023 | CRS | Director Stock Options (Right to Buy) | Common Stock (1,028) | $70.64 | Oct. 10, 2033 | 1,028 | Acquired |
| Oct. 10, 2023 | CRS | Director Stock Units | Common Stock (1,912) | — | — | 1,912 | Acquired |
| June 16, 2023 | DNA | Stock Option | Class A Common Stock | $1.90 | June 16, 2033 | 139,860 | Acquired |
| June 16, 2023 | DNA | Restricted Stock Units | Class A Common Stock (105,263) | — | — | 105,263 | Acquired |
| May 18, 2023 | OTIS | Deferred Stock Units | Common Stock (2,308) | — | — | 2,308 | Acquired |
| Oct. 11, 2022 | CRS | Director Stock Options (right to buy) | Common Stock (2,408) | $34.30 | Oct. 11, 2032 | 2,408 | Acquired |
| Oct. 11, 2022 | CRS | Director Stock Units | Common Stock (3,646) | — | — | 3,646 | Acquired |
| Aug. 2, 2022 | DNA | Stock Option | Class A Common Stock | $2.14 | Aug. 2, 2032 | 186,915 | Acquired |
| Aug. 2, 2022 | DNA | Stock Option | Class A Common Stock | $2.03 | Aug. 2, 2032 | 84,216 | Acquired |
| May 19, 2022 | OTIS | Deferred Stock Units | Common Stock (2,686) | — | — | 2,686 | Acquired |
| April 13, 2022 | CRS | Director Stock Option (right to buy) | Common Stock (4,991) | $40.73 | April 13, 2032 | 4,991 | Acquired |
| April 13, 2022 | CRS | Director Stock Units | Common Stock (1,324) | — | — | 1,324 | Acquired |
| April 27, 2021 | OTIS | Deferred Stock Units | Common Stock (2,468) | — | — | 2,468 | Acquired |
| May 11, 2020 | OTIS | Deferred Stock Units | Common Stock (3,764) | — | — | 3,764 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.